NCT00934323已完成1 期
An Open, Randomized, Two-Treatment, Crossover Study to Assess the Dose Proportionality of Glimepiride Between Amaryl M SR 1/500mg and 2/500mg (Glimepiride-Metformin Fixed Dose Combination Tablet) in Healthy Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Handok Inc.
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- AUClast/D, Cmax/D
研究概览
简要总结
The pharmacokinetics of glimepiride and metformin will be compared after single dose intake of both combinations in order to answer to the following questions:
- Is there a dose proportionality effect between Amaryl M SR 1/500 mg and Amaryl M SR 2/500 mg?
- What is the safety profile of Amaryl M SR 1/500 mg and Amaryl M SR 2/500 mg?
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Age: Between 20 to 45 years of age, inclusive (Age based on the date to give the informed consent)
- •Ideal body weight (Broca index): between 50 to 90 kg, inclusive, and within ±20 % of Ideal Body Weight, [(Height in cm-100)×0.9]
- •Subjects who are appropriate to participate in this study judged from clinical laboratory and physical examinations taken within 4weeks prior to the start of study
- •Subjects who are able to abstain from caffein or caffein-containing products (e.g., coffee, cola, tea, chocolate), grapefruit and grapefruit containing products, alcohol and smoking within 72 hours before dosing and during the hospitalization
- •Subjects who are reliable and willing to make themselves available during the study period, are willing to follow the study protocol, and give their written informed consent voluntarily
排除标准
- •History of allergies including drug allergy, except untreated, asymptomatic, seasonal allergies at the time of dosing
- •Use any prescriptive medication, Korean traditional medication not considered acceptable by the clinical investigator during the last 10 days period before first dosing, or use any OTC medication not considered acceptable by the clinical investigator during the last 7 days period before first dosing (If used medication is considered acceptable by investigator, patients can be included)
- •History of significant clinical illness needs medical caution, including cardiovascular, immunologic, hematologic, neuropsychiatric, respiratory, gastrointestinal, hepatic, or renal disease or other chronic disease
- •History of a significant surgical resection of gastrointestinal tract except appendectomy
- •Abnormal clinical laboratory findings, especially for AST or ALT> 1.25 fold of upper normal limit
- •Evidence of alcohol abuse (defined as regular alcohol intake that exceeds 24 oz [675 ml] of beer, 12 oz [340 ml] of wine or 160 ml of soju or 3 oz [85 ml] hard liquor [e.g., brandy, whiskey, gin] per day) or drug abuse
- •Heavy smokers (> 10 cigarettes per day), or can't quit smoking during hospitalization
- •Participation in clinical trials of any drug within 3 months prior to the participation of the study
- •Donation of whole blood within 2 months or a unit of blood within 1 month prior to the start of study [Day 1].
- •Positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or HIV antibody
- •Judged to be inappropriate for the study by the investigator
研究组 & 干预措施
TR sequential group
Experimental
Amaryl M SR 1/500 mg in period 1 and Amaryl M SR 2/500 mg in period 2
干预措施: Amaryl M SR 1/500 mg (Drug)
TR sequential group
Experimental
Amaryl M SR 1/500 mg in period 1 and Amaryl M SR 2/500 mg in period 2
干预措施: Amaryl M SR 2/500 mg (Drug)
RT sequential group
Active Comparator
Amaryl M SR 2/500 mg in period 1 and Amaryl M SR 1/500 mg in period 2
干预措施: Amaryl M SR 1/500 mg (Drug)
RT sequential group
Active Comparator
Amaryl M SR 2/500 mg in period 1 and Amaryl M SR 1/500 mg in period 2
干预措施: Amaryl M SR 2/500 mg (Drug)
结局指标
主要结局
AUClast/D, Cmax/D
时间窗: pre-dose (=1d 0h), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 15, 24 hrs after drug administration
次要结局
- Tmax, T1/2(pre-dose (=1d 0h), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 15, 24 hrs after drug administration)
- Vital signs, ECG, physical examination, clinical laboratory tests(screening, treatment period 1 & 2, Post-study visit)
- Adverse Event(Treatment period 1 & 2, Post-study visit)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Dose Proportionality Study Comparing Amaryl-M 1/500 mg and Amaryl-M 2/500 mgHealthyNCT00934817Handok Inc.36
已完成
3 期
Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately ControlledType 2 Diabetes MellitusNCT01699932Sanofi167
已完成
3 期
Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes PatientsDiabetes Mellitus, Type 2NCT01459809Sanofi538
已完成
3 期
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With MetforminType 2 Diabetes MellitusNCT01457911Sanofi244
已完成
1 期
Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy ParticipantsHealthyNCT03467945Merck KGaA, Darmstadt, Germany40